期刊
BIOLOGICAL PSYCHIATRY
卷 88, 期 8, 页码 657-667出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2020.04.009
关键词
Antidepressant response; Biomarkers; Bupropion; Frontostriatal connectivity; Reward sensitivity; Sertraline
资金
- National Institute of Mental Health (NIMH) [U01MH092221, U01MH092250]
- A*STAR National Science Scholarship [R37 MH068376]
- EMBARC National Coordinating Center at UT Southwestern Medical Center
- Data Center at Columbia University
- Data Center at Stony Brook University
- Agency for Healthcare Research and Quality
- Cyberonics Inc.
- National Alliance for Research in Schizophrenia and Depression (NARSAD)
- NIMH
- National Institute on Drug Abuse (NIDA)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Johnson Johnson
- Acadia Pharmaceuticals
- Allergan
- Alkermes, Inc.
- BioClinica, Inc.
- Biogen
- BioHaven
- Cambridge Science Corporation
- Cerecor
- Gate Neurosciences, Inc.
- GenOmind, LLC
- Gentelon, LLC
- Happify
- Lundbeck Inc.
- Marinus Pharmaceuticals
- Methylation Sciences, Inc.
- Millennium Pharmaceutics, Inc.
- Minerva Neurosciences
- Neuralstem
- NeuroRX Inc.
- Novartis
- Otsuka
- Pfizer
- Premiere Research International
- Relmada Therapeutics Inc.
- Reckitt
- Shenox Pharmaceuticals
- Stanley Medical Research Institute
- Taisho
- Takeda
- Vistagen
- NIDA
- NIH
- PCORI
- NARSAD
- Sackler Foundation
- Templeton Foundation
- Patient-Centered Outcomes Research Institute (PCORI)
- Tourette Syndrome Association
- International OCD Foundation
- Tufts University
- Depression and Bipolar Alternative Treatment Foundation
- Otsuka Pharmaceuticals
- Cogito Inc.
- Sunovion
- Assurex Pharmaceuticals
- Assurex
- Defense Advanced Research Projects Agency
- National Institute on Aging
- Janssen Pharmaceuticals
- Forest Research Institute
- Shire Development
- Medtronic
- Cyberonics
- NorthStar
- Brain and Behavior Research Foundation
- Dana Foundation
- Millennium Pharmaceuticals
BACKGROUND: Standard guidelines recommend selective serotonin reuptake inhibitors as first-line antidepressants for adults with major depressive disorder, but success is limited and patients who fail to benefit are often switched to non-selective serotonin reuptake inhibitor agents. This study investigated whether brain- and behavior-based markers of reward processing might be associated with response to bupropion after sertraline nonresponse. METHODS: In a two-stage, double-blinded clinical trial, 296 participants were randomized to receive 8 weeks of sertraline or placebo in stage 1. Individuals who responded continued on another 8-week course of the same intervention in stage 2, while sertraline and placebo nonresponders crossed over to bupropion and sertraline, respectively. Data from 241 participants were analyzed. The stage 2 sample comprised 87 patients with major depressive disorder who switched medication and 38 healthy control subjects. A total of 116 participants with major depressive disorder treated with sertraline in stage 1 served as an independent replication sample. The probabilistic reward task and resting-state functional magnetic resonance imaging were administered at baseline. RESULTS: Greater pretreatment reward sensitivity and higher resting-state functional connectivity between bilateral nucleus accumbens and rostral anterior cingulate cortex were associated with positive response to bupropion but not sertraline. Null findings for sertraline were replicated in the stage 1 sample. CONCLUSIONS: Pretreatment reward sensitivity and frontostriatal connectivity may identify patients likely to benefit from bupropion following selective serotonin reuptake inhibitor failures. Results call for a prospective replication based on these biomarkers to advance clinical care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据